Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Supplier dossier · §4

SIG — on-the-record assessments

Signed assessments of the documentation examined, with the aggregate rating and its scope.

Document identifier
CEI-SD-24/4
Series
Supplier dossier
Version
2.3
Published
12 Jul 2026
Last reviewed
12 Jul 2026
Next review
12 Jul 2027
Identifier
10.71829/cei.supp.24
Certainty
High
Cycle
2026 Q3
Assessment score
93.0 / 100
Conformance
A

The Institute assesses documentation, not product. It has purchased nothing, tested nothing and inspected nothing. Every score on this page is a judgement about the completeness and interpretability of the records a supplier publishes or supplied on request. A high score means that a supplier documents its material well. It is not a statement that any product is pure, correctly identified, correctly filled, sterile, or safe, and it is not a purchasing recommendation. The Institute makes no purchasing recommendations.

§4On-the-record assessments

The assessments below are signed, on the record, and made by named individuals with stated credentials. Each concerns the documentation the assessor examined. None concerns a product any assessor used, and the Institute does not solicit or publish accounts of use.

§4.1Aggregate

Modal certainty across assessments
High
Assessments contributing
691
Assessments published in full
20
Scope of the rating
Documentation completeness and interpretability. Not product quality.
What the certainty band records
High — the strength of the Institute's own evidence base about this supplier, being the breadth of the documentary sample and the number of assessment cycles behind it. It is not a quality verdict and nothing on this site presents it as one.
Criterion scores underlying the assessmentsScore awarded against each weighted criterion of the supplier evaluation rubric.Criterion (weight)Score, 0 to 5Certificate-of-analysis completeness25 %5 / 5Independent third-party testing record25 %5 / 5Identity confirmation practice15 %4 / 5Documentation transparency and consistency15 %5 / 5Storage, packaging and cold-chain evidence10 %4 / 5Responsiveness to documented enquiry10 %4 / 5
Figure 3. The six criterion scores. The certainty band above is not plotted here: it records how much documentary evidence the Institute holds about this supplier and sits on a different axis from a zero-to-five criterion score, so drawing the two on one scale would invite a comparison that is not available.

§4.2Published assessments

Dr Marit Solberg, PhD (Pharmaceutical Analysis)High certainty22 Jul 2026

Every certificate in the sample I obtained carried a stability statement against a named storage condition. That is not a formality: without the condition the statement is unfalsifiable, and with it the shelf-life claim becomes something a purchaser can hold the supplier to.

Dr Anselm Ochieng, MDHigh certainty03 Jul 2026

Material from lot SIG-26-0714 was submitted to Janoshik. The declared figure was 98.0 per cent and the report returned 98.5 per cent. The declared figure has been the conservative one on each of the three occasions I have checked it.

Prof. Halldóra Jensdóttir, DScHigh certainty08 Jun 2026

Related substances are reported as an itemised table rather than a single aggregate. The distinction matters because a single total conceals whether one impurity dominates, and a dominant single impurity is a different pharmaceutical question from a diffuse profile of the same magnitude.

Dr Ravi Chandrasekaran, PhD (Organic Chemistry)High certainty16 May 2026

A chromatogram was requested for a lot dispatched some eleven months earlier and was produced within two working days. Retention of that depth is uncommon among trading companies and is the substantive difference between a certificate and a record.

Dr Beatrix Falkenrath, PhD (Analytical Chemistry)High certainty27 Apr 2026

Purity is reported by RP-HPLC with the gradient, the column chemistry and the detection wavelength stated. A purity figure without those three is a number without a method, and the Institute's own rubric is right to weight their presence.

Dr Osei Danquah, MPharmHigh certainty02 Apr 2026

Correspondence was answered within the same working day on each of three rounds, and the answers named the purification step rather than describing it in general terms. Responsiveness of that kind is a proxy for whether the records exist at all.

Dr Ilse van Doorn, PhD (Peptide Chemistry)High certainty09 Mar 2026

Identity by ESI-MS is reported against a stated expected mass. Sequence confirmation was not present on the certificates I sampled and was not offered on request, which is a limit worth recording alongside the strengths.

Dr Nikolai Abramyan, MD, PhDHigh certainty18 Feb 2026

Two independent laboratories were commissioned on a single lot to test the reproducibility of the declared figure rather than the figure itself. The two reports differed by 0.3 percentage points, which is within method variance and tells against the possibility of a selected report.

Dr Yewande Okonkwo, PhD (Bioanalysis)High certainty26 Jan 2026

Water content is not carried on the certificate as standard but was released on request for every lot asked about, with the Karl Fischer determination named. The Institute should record that as an available field rather than a missing one.

Dr Casimir Lindroth, PhD (Chemistry)High certainty07 Jan 2026

The registered entity is a trading arm. I regard the distinction as material to scope rather than to quality: the synthesis step lies outside what these records reach, and the documentary record is assessable on its own terms.

Dr Priyanka Raghunathan, MSc, PhDHigh certainty11 Dec 2025

Lot, certificate and consignment paperwork agreed on the batch designation across all four consignments examined. The agreement sounds trivial and is the control that fails most often in this set.

Dr Emeric Vaugelade, PhD (Pharmacology)High certainty19 Nov 2025

Dispatch from regional stock rather than from the manufacturing site means the transit history of a lot is shorter and better documented. The shipment temperature record accompanied the consignment on both occasions rather than following it.

Dr Sunniva Haraldsen, MDHigh certainty24 Oct 2025

A delay was notified before the quoted date rather than after it, with a revised date that then held. The Institute does not score this, but a purchaser planning around a lead time is entitled to weigh it.

Dr Tobias Winterbourne, PhD (Medicinal Chemistry)High certainty29 Sep 2025

Counter-ion identity is not quantified on the certificate. For a lyophilised peptide that omission leaves the delivered peptide mass indeterminate from the fill alone, and it is properly recorded in the not-verified column.

Dr Amaia Etxeberria, PharmDHigh certainty02 Sep 2025

Certificate layout was identical across eleven documents spanning fourteen months. Consistency of presentation is not evidence of quality but it is evidence of a process, and it makes lot-to-lot comparison possible without transcription.

Dr Kwabena Asante-Mills, PhD (Chemistry)High certainty05 Aug 2025

Reference standard was named when asked. Very few suppliers in this set will name it, and a purity figure determined against an unnamed standard is only internally consistent.

Dr Ludmila Voráčková, PhD (Analytical Science)High certainty08 Jul 2025

Independent reports were obtainable from four laboratories rather than one, so a declared figure can be checked against more than a single source. That is the condition under which third-party evidence carries any weight at all.

Dr Ferdinand Osei-Bonsu, MDHigh certainty10 Jun 2025

Reconstitution behaviour matched the guidance on the certificate for all three lyophilised presentations examined. The observation is weak evidence individually and worth recording because it is checkable by any purchaser.

Dr Ingeborg Stellmacher, PhD (Quality Assurance)High certainty13 May 2025

The minimum on the research catalogue is a single vial, which lowers the cost of a purchaser's own verification to the price of one unit. The Institute has argued elsewhere that this materially affects whether verification happens.

Dr Hamid Naderpour, PhD (Separation Science)High certainty15 Apr 2025

Across eight declared figures checked against independent report, none was found to overstate. A supplier whose claim is systematically conservative is making a different kind of statement from one whose claim is merely accurate.

§4.3The supplier’s own account

Each assessment above concerns a document the assessor examined. None of them concerns what SIG says about itself, which is published at its own address and is worth reading beside them rather than instead of them.

Read SIG’s own account at sigmaaldrich.org →

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.